ValoreQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25TTMSpese di vendita, generali e amministrative60.8 M52.4 M43.7 M38.9 M51.1 M186.1 MRicerca e sviluppo9.1 M15.1 M12.5 M13.5 M12.1 M53.2 MReddito operativo-9.5 M49.9 M1.6 M76.5 M-27.9 M100.1 MProventi non operativi, Totale-18.1 M42.8 M-18.4 M-18.9 M-22.8 M-17.3 MOneri finanziari, al netto degli interessi capitalizzati14.8 M14.7 M14.7 M15.2 M14.7 M59.3 MProventi non operativi, esclusi gli oneri finanziari-29.6 M-41.6 M-29.4 M-30.4 M-29.4 M-130.8 MEntrate/uscite straordinarie-3.3 M69.7 M-3.7 M-3.7 M-8.1 M54.2 MUtile al lordo delle imposte-27.6 M92.7 M-16.8 M57.6 M-50.7 M82.8 MQuota di utile——————Imposte3.7 M24.7 M-4.8 M6.4 M3.9 M30.2 MInteressi di minoranza——————Altri proventi/oneri al netto delle imposte-2.6 M11.3 M-2.2 M-400 K-9.1 M-400 KUtile netto al lordo delle attività cessate-31.3 M68 M-12 M51.2 M-54.6 M52.6 MAttività cessate——————Utile netto-31.3 M68 M-12 M51.2 M-54.6 M52.6 MRegolazione della diluizione——————Dividendi privilegiati——————Utile netto diluito attribuibile agli azionisti ordinari-31.3 M68 M-12 M51.2 M-54.6 M52.6 MUtile base per azione (EPS base)-0.551.25-0.220.96-1.010.98Utile diluito per azione (EPS diluito)-0.451.19-0.220.91-0.950.93Numero medio di azioni ordinarie in circolazione53 M54.4 M54.2 M53.2 M53.5 M215.3 MAzioni diluite in circolazione53 M57.3 M54.2 M56.5 M56.7 M224.7 MEBITDA-44.5 M-65.3 M-84.5 M-22.7 M-139.4 M-311.9 MEBIT-70.1 M-91.3 M-110 M-50.5 M-164.9 M-416.7 MCosto del fatturato—88.5 M66.9 M85.9 M84.9 M326.2 MAltri costi del venduto——————Ammortamento e svalutazione (liquidità)26 M25.4 M23.5 M23.4 M23.5 M95.8 M
Emergent BioSolutions Inc
Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes.
Among the company's products are the controversial BioThrax, the only anthrax vaccine licensed by the U.S. Food and Drug Administration and Narcan for the emergency treatment of opioid overdose. The company also manufactures pharmaceuticals for infectious diseases like cholera and typhoid.
During the COVID-19 pandemic, Emergent BioSolutions also produced Johnson & Johnson/Janssen and Oxford–AstraZeneca vaccines at one of its plants; however, this was marked by contamination and other production issues, and millions of doses of vaccine had to be discarded.